- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Navitoclax, Osimertinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 18
- States / cities
- Sacramento, California • Aurora, Colorado • Tampa, Florida + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 1,117
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors
- Interventions
- AMG 794
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 1 more
- Conditions
- Lung Cancer
- Interventions
- BAY 43-9006, Paclitaxel, Carboplatin, Bevacizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Arm A: Pemetrexed Cisplatin, Arm B Pemetrexed, Cisplatin and MK-0646
- Drug
- Lead sponsor
- University of Kansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 4
- States / cities
- Hutchinson, Kansas • Kansas City, Kansas • Topeka, Kansas + 1 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Atezolizumab, Tiragolumab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 11
- States / cities
- Tempe, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 8 more
- Conditions
- Cancer
- Interventions
- therapeutic allogeneic lymphocytes
- Biological
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- Not listed
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Sacituzumab Govitecan, Pembrolizumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 16
- States / cities
- Mobile, Alabama • Oceanside, California • Clermont, Florida + 12 more
- Conditions
- Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Sotorasib
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 828
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 561 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- docetaxel, pemetrexed disodium, gemcitabine hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- pemetrexed, pemetrexed + PF-3512676
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 17
- States / cities
- Litchfield Park, Arizona • Sun City, Arizona • Bentonville, Arkansas + 12 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ivonescimab Injection, Pembrolizumab Injection
- Biological
- Lead sponsor
- Summit Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 61 more
- Conditions
- Lung Cancer
- Interventions
- bevacizumab, carboplatin, erlotinib hydrochloride, pemetrexed disodium
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 4
- States / cities
- Asheville, North Carolina • Chapel Hill, North Carolina • New Bern, North Carolina + 1 more
- Conditions
- Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
- Interventions
- SLC-391, pembrolizumab
- Drug · Biological
- Lead sponsor
- SignalChem Lifesciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Abemaciclib, Erlotinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 54
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • Duarte, California + 39 more
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Chemotherapy, Pembrolizumab, Ramucirumab
- Drug · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 838 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 566
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Gilteritinib, Magnetic Resonance Imaging, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- San Marcos, California
- Conditions
- Lung Cancer
- Interventions
- docetaxel, vinorelbine tartrate
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 96
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- Non-small Cell Lung Cancer NSCLC
- Interventions
- Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 9
- States / cities
- Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more
- Conditions
- Lung Cancer
- Interventions
- erlotinib hydrochloride, gene expression analysis, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, needle biopsy
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
- Interventions
- Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
- Conditions
- Carcinoma
- Interventions
- osimertinib, savolitinib, placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 11
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 8 more
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Interventions
- Taxotere (Docetaxel), Alimta (Pemetrexed)
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed, HER3-DXd
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 5
- States / cities
- Lexington, Kentucky • Baltimore, Maryland • Fargo, North Dakota + 2 more